A retrospective review of the frequency of infections and patterns of antibiotic utilization on a palliative care unit

Journal of Pain and Symptom Management

Volumn 16, Issue 6, 1998, Pages 374-381

  Pereira, Jose ^a   Watanabe, Sharon ^a   Wolch, Gary ^a  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFALOTIN; CEFAZOLIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; CORTICOSTEROID; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; METRONIDAZOLE; NITROFURANTOIN; NORFLOXACIN; OXACILLIN; PIPERACILLIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; CANCER PATIENT; DRUG UTILIZATION; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PALLIATIVE THERAPY; REVIEW;

EID: 0032414538     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(98)00093-1     Document Type: Article

References (53)

1. Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol/Oncol Clin North Am. 7(4):1993;771-793.
2. Inagaki J., Rodriguez V., Bodey G.P. Causes of death in cancer patients. Cancer. 33(2):1974;568-573.
3. Klastersky J., Daneau D., Verhest A. Causes of death in patients with cancer. Europ J Cancer. 8:1972;149-154.
4. Rossini F. Prognosis of infections in elderly patients with haematological diseases. Support Care Cancer. 4:1996;46-50.
5. Rossi C., Klastersky J. Initial empirical antibiotic therapy for neutropenic fever. analysis of the causes of death Support Care Cancer. 4:1996;207-212.
6. Giamarellou H. Empiric therapy for infections in the febrile, neutropenic, compromised host. In: Cullen JH, Jacobs CC, eds. The medical clinics of North America. Philadelphia: W.B. Saunders, 1995;79(3):559-580.
7. Klastersky J. Therapy of infections in cancer patients. In: Klastersky J, Schimpff SC, Senn HJ, eds. Handbook of supportive care in cancer. New York: Marcel Dekker, 1995;1:1-44.
8. Lagman R, Panta R, Walsh D. Infectious Complications in Advanced Cancer. 8th International Symposium, Abstracts. Support Care Cancer 1996;4:226.
9. Kuehn N, MacEachern T, Miller M, Spachynski K. Nosocomial infections (NI) on a palliative care unit (PCU): a prospective comparison study. Poster for 9th International Congress on Care of the Terminally Ill, Montreal Canada, 1992; Oct. 31-Nov. 2.
10. Rotstein C., Cummings K.M., Nicolaou A.L.et al. Nosocomial infection rates at an oncology center. Infect Control Hosp Epidemiol. 9(113-19):1988.
11. Ayliffe G.A., Casewell M.W., Cookson B.D.et al. National prevalence survey of hospital acquired infections. definitions J Hospital Infect. 24:1993;69-76.
12. Garner J.S.et al. CDC definitions for nosocomial infections. Am J Infect Control. 16:1988;128-140.
13. Hughes WT, Flynn PM, Williams BG. Nosocomial infection in patients with neoplastic diseases. In: Mayhall CG, ed. Hospital epidemiology and infection control. Baltimore: Williams and Wilkins, 1996;43:618-631.
14. Curnette JT, Boxer LA. Clinically significant phagocytic cell defects. In: Remington J, Swartz M, eds. Current clinical topics in infectious diseases. New York: McGraw Hill, 1985;6:103-156.
15. Keusch GT. Nutrition and infection. In: Remington JS, Swartz NM, eds. Current clinical topics in infectious disease. New York: McGraw Hill, 1984;5:106-123.
16. Glauser M.P., Zinner S.H. Mechanisms of acquisition and development of bacterial infections in cancer patients. Klastersky J. Infections in cancer patients. 1982;13-24 Raven Press, New York.
17. Warren JW. Nosocomial urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995;283:2607-2616.
18. Shapiro M., Greenfield S. The complete blood count and leucocyte differential count. Ann Intern Med. 106:1987;65-74.
19. Wasserman M., Levinstein M., Keller E.et al. Utility of fever, white blood cells, and differential count in predicting bacterial infections in the elderly. J Am Geriatr Soc. 37:1989;537-543.
20. Hodkinson H.M. Common symptoms of disease in the elderly. 2:1989;Blackwell, Oxford.
21. Haynes R.C. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. Goodman L., Gilman A. The pharmacological basis of therapeutics. 1990;1431-1462 Pergamon Press, New York.
22. Pereira J., Hanson J., Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer. 79:1997;835-842.
23. Johnson M. Neoplastic fever. Palliative Med. 10:1996;217-224.
24. Martone WJ, Jarvis WR, Culver DH, Haley RW. Incidence and nature of endemic and epidemic nosocomial infections. In: Bennett JV, Brachman PS, Sanford JP, eds. Hospital infections, 3rd ed. Boston: Little, Brown, 1992;27:577-596.
25. Magaziner J., Tenney J.H., DeForge B.et al. Prevalence and characteristics of nursing home-acquired infections in the aged. JAGS. 39:1991;1071-1078.
26. Smith M.A., Duke W.M. A retrospective review of nosocomial infections in an acute rehabilitative and chronic population at a large skilled nursing facility. JAGS. 42:1994;45-49.
27. LaForce FM. Lower respiratory tract infections. In: Bennett JV, Brachman PS, Sanford JP, eds. Hospital infections, 3rd ed. Boston: Little, Brown, 1992;29:611-639.
28. Wong ES. Surgical site infections. In: Mayhall CG, ed. Hospital epidemiology and infection control. Baltimore: Williams & Wilkins, 1996;11:168-175.
29. Fainsinger R.L., MacEachern T., Miller M.J.et al. The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symptom Manage. 9(5):1994;298-302.
30. Bruera E., Legris M.A., Kuehn N., Miller M.J. Hypodermoclysis for the administration of fluids and narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage. 5(4):1990;218-220.
31. Robinson G.V., Tegtmeier B.R., Zaia J.A. Brief report. nosocominal infection rates in a cancer treatment center Infect Control. 5:1984;289-294.
32. George DL. Nosocomial pneumonia. In: Mayhall CG, ed. Hospital epidemiology and infection control. Baltimore: Williams & Wilkins, 1996;12:175-195.
33. Woods GL, Washington JA. The clinician and the microbiology laboratory. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995;11:169-199.
34. Cote L. Clinical characteristics of skin and soft tissue infections. Canadian J CME 1995;37-45.
35. Morrison V.A., Peterson B.A., Bloomfield C.D. Nosocomial septicemia in the cancer patient. the influence of central venous access devices, neutropenia, and type of malignancy Med Pediatr Oncol. 18:1990;209-216.
36. Singer C., Kaplan M.H., Armstrong D. Bacteremia and fungemia complicating neoplastic disease. a study of 364 cases Am J Med. 62:1977;731-742.
37. Schimpff S.C. Gram-negative bacteremia. Support Care Cancer. 1:1993;5-18.
38. Pittet D., Wenzel R.P. Nosocomial bloodstream infections. Arch Intern Med. 155:1995;1177-1184.
39. Mayo J.W., Wenzel R. Rates of hospital-acquired bloodstream infections in patients with specific malignancy. Cancer. 50:1982;187-190.
40. Bruera E. Intractable pain in patients with advanced head and neck tumors. a possible role of local infection Cancer Treat Rep. 70(5):1986;691-692.
41. Green K., Webster H., Watanabe S., Fainsinger R. Case report. management of nosocomial respiratory tract infections in terminally ill cancer patients J Palliative Care. 10(4):1994;31-34.
42. MacKey J., Birchall I., MacDonald N. Occult infection as a cause of hip pain in a patient with metastatic breast cancer. J Pain Symptom Manage. 10(7):1995;569-572.
43. Council on Ethical and Judicial Affairs, American Medical Association. Decisions near the end of life. JAMA 1992;267(16):2229-2233.
44. Craig WA, Andes DR. Parenteral versus oral antibiotic therapy. In: Cunha BA, ed. The medical clinics of North America. Philadelphia: W.B. Saunders, 1995;79(3):497-508.
45. Ma MY, Rho JP. Considerations in antimicrobial prescribing. In: Cunha BA, ed. The medical clinics of North America. Philadelphia: W.B. Saunders, 1995;79(3):537-549.
46. French GL, Phillips I. Antimicrobial resistance in hospital flora and nosocomial infections. In: Mayhall CG, ed. Hospital epidemiology and infection control. Baltimore: Williams & Wilkins, 1996;74:980-999.
47. Hartstein A.I., Garber S.B., Ward T.T., Jones S.R., Morthland V.H. Nosocomial urinary tract infection. a prospective evaluation of the 108 catheterized patients Infect Control. 2:1981;380-386.
48. Fainsinger R.L., MacEachern T., Hanson J., Bruera E. The use of urinary catheters in terminally ill cancer patients. J Pain Symptom Manage. 7(6):1992;333-338.
49. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis II. 6):1989;954-963.
50. Watanabe S., Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage. 9(7):1994;442-445.
51. Chye R., Lickiss N. Palliative care rounds. the use of corticosteroids in the management of bilateral malignant ureteric obstruction J Pain Symptom Manage. 9(8):1994;537-540.
52. Fainsinger R.L., Spachynski K., Hanson J., Bruera E. Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manage. 9(1):1994;12-18.
53. Bruera E., Seifert L., Watanabe S., Babul N., Darke A., Harsanyi Z., Suarez-Almazor M. Chronic nausea in advanced cancer patients. a retrospective assessment of a metoclopramide-based antiemetic regimen J Pain Symptom Manage. 11(3):1996;147-153.